These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17575026)

  • 1. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis.
    Baek WS; Bashey A; Sheean GL
    J Neurol Neurosurg Psychiatry; 2007 Jul; 78(7):771. PubMed ID: 17575026
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis.
    Burusnukul P; Brennan TD; Cupler EJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):85-7. PubMed ID: 21386776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in refractory MuSK antibody myasthenia gravis.
    Thakre M; Inshasi J; Marashi M
    J Neurol; 2007 Jul; 254(7):968-9. PubMed ID: 17468964
    [No Abstract]   [Full Text] [Related]  

  • 4. Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment.
    Lau AY; Chan AY; Mok VC
    Hong Kong Med J; 2011 Feb; 17(1):77-9. PubMed ID: 21282832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.
    Hain B; Jordan K; Deschauer M; Zierz S
    Muscle Nerve; 2006 Apr; 33(4):575-80. PubMed ID: 16323216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.
    Keung B; Robeson KR; DiCapua DB; Rosen JB; O'Connor KC; Goldstein JM; Nowak RJ
    J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1407-9. PubMed ID: 23761915
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.
    Koul R; Al Futaisi A; Abdwani R
    Pediatr Neurol; 2012 Sep; 47(3):209-12. PubMed ID: 22883288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.
    Stein B; Bird SJ
    J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497
    [No Abstract]   [Full Text] [Related]  

  • 11. Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis.
    Catzola V; Battaglia A; Buzzonetti A; Fossati M; Scuderi F; Fattorossi A; Evoli A
    J Neurol; 2013 Aug; 260(8):2163-5. PubMed ID: 23749295
    [No Abstract]   [Full Text] [Related]  

  • 12. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
    Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA
    Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503
    [No Abstract]   [Full Text] [Related]  

  • 13. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis.
    Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C
    Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis.
    Roda RH; Doherty L; Corse AM
    Neuromuscul Disord; 2019 Jul; 29(7):554-561. PubMed ID: 31296355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for myasthenia gravis developing after bone marrow transplant.
    Zaja F; Russo D; Fuga G; Perella G; Baccarani M
    Neurology; 2000 Oct; 55(7):1062-3. PubMed ID: 11061276
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to rituximab in an anti-muscle-specific receptor tyrosine kinase- and anti-acetylcholine recepto-double-positive myasthenia gravis patient concomitant with follicular dendritic cell sarcoma.
    Wang J; Wu X; Deng H; Liu Y; Liu H; Fan X; Liu K; Wu J; Zhang HL
    Neurosciences (Riyadh); 2016 Jan; 21(1):77-8. PubMed ID: 26818174
    [No Abstract]   [Full Text] [Related]  

  • 17. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.
    Gajra A; Vajpayee N; Grethlein SJ
    Am J Hematol; 2004 Oct; 77(2):196-7. PubMed ID: 15389902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.
    Jonsson DI; Pirskanen R; Piehl F
    Neuromuscul Disord; 2017 Jun; 27(6):565-568. PubMed ID: 28433474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
    Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E
    J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lasting treatment effect of rituximab in MuSK myasthenia.
    Díaz-Manera J; Martínez-Hernández E; Querol L; Klooster R; Rojas-García R; Suárez-Calvet X; Muñoz-Blanco JL; Mazia C; Straasheijm KR; Gallardo E; Juárez C; Verschuuren JJ; Illa I
    Neurology; 2012 Jan; 78(3):189-93. PubMed ID: 22218276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.